Equities

Hillevax Inc

HLVX:NSQ

Hillevax Inc

Actions
  • Price (USD)15.72
  • Today's Change0.10 / 0.64%
  • Shares traded25.16k
  • 1 Year change+2.14%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 17:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

  • Revenue in USD (TTM)0.00
  • Net income in USD-123.57m
  • Incorporated2020
  • Employees90.00
  • Location
    Hillevax Inc321 Harrison Ave, Suite 500BOSTON 02118United StatesUSA
  • Phone+1 (617) 213-5054
  • Fax+1 (617) 213-5054
  • Websitehttps://www.hillevax.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zymeworks Inc76.01m-118.67m726.85m272.00--1.57--9.56-1.74-1.741.106.570.1236--2.88279,455.90-19.30-22.58-22.01-26.90-----156.13-91.17----0.0003---81.577.47-195.44--3.58--
Exscientia PLC (ADR)30.92m-181.88m728.97m481.00--1.45--23.58-1.46-1.460.24843.980.04--2.4064,272.87-23.54---26.71---26.74---588.31------0.0445---0.4971---141.17------
Wave Life Sciences Ltd113.31m-57.51m738.60m266.00--18.16--6.52-0.5397-0.53971.070.39870.5378----425,958.70-27.30-56.98-70.41-102.38-----50.76-353.20----0.00--3,005.1051.0464.46---35.44--
OPKO Health Inc863.49m-188.86m745.78m3.93k--0.5956--0.8637-0.2513-0.25131.151.800.41337.806.89219,718.60-9.03-7.14-10.03-8.1436.8434.42-21.86-13.831.22-15.240.1574---14.01-2.7042.49---10.19--
Astria Therapeutics Inc0.00-72.89m746.68m59.00--3.78-----2.34-2.340.005.920.00----0.00-30.04-64.48-31.37-68.34------------0.00-------40.62------
enGene Holdings Inc0.00-106.80m751.34m33.00--6.41-----4.60-4.600.002.69------0.00-------------------1.370.2653-------260.87------
Allogene Therapeutics Inc95.00k-327.27m754.15m232.00--1.47--7,938.42-2.09-2.090.00063.040.0001----409.48-44.70-28.46-47.65-30.21-----344,489.50-1,123.44----0.00---39.10--3.86---14.06--
Longboard Pharmaceuticals Inc0.00-54.42m755.64m50.00--12.57-----2.39-2.390.001.670.00----0.00-89.72---105.91--------------0.00-------23.84------
Cullinan Oncology Inc0.00-153.16m763.55m85.00--1.68-----3.70-3.700.0010.580.00----0.00-29.68-12.37-31.19-12.93-------1,026.78----0.00-------237.72---4.44--
Hillevax Inc0.00-123.57m776.33m90.00--2.80-----3.04-3.040.005.570.00----0.00-37.35---39.90--------------0.0868------22.68------
Nkarta Inc0.00-117.50m778.07m150.00--1.99-----2.40-2.400.005.560.00----0.00-27.59-32.39-29.14-34.05-------372,519.20----0.00-------3.22--106.05--
Praxis Precision Medicines Inc2.45m-123.28m783.71m82.00--7.47--320.27-23.64-23.640.37197.920.0241----29,841.46-121.41-74.04-161.17-85.12-----5,037.88-24,589.25----0.00------42.40---4.52--
Aerovate Therapeutics Inc0.00-75.52m794.09m51.00--7.23-----2.87-2.870.003.940.00----0.00-57.49---63.65--------------0.00-------46.61------
Prime Medicine Inc0.00-198.13m810.79m234.00--4.95-----2.17-2.170.001.370.00----0.00-71.51---84.13-------------85.970.00-------39.52------
Tango Therapeutics Inc36.53m-101.74m821.73m140.00--3.11--22.50-1.08-1.080.38652.480.0871--36.53260,907.10-24.25---27.59-------278.54------0.00--46.93--5.95------
Data as of Mar 28 2024. Currency figures normalised to Hillevax Inc's reporting currency: US Dollar USD

Institutional shareholders

24.29%Per cent of shares held by top holders
HolderShares% Held
Deep Track Capital LPas of 31 Dec 20232.90m5.99%
Franklin Advisers, Inc.as of 31 Dec 20231.85m3.81%
BlackRock Fund Advisorsas of 31 Dec 20231.63m3.37%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20231.45m3.00%
The Vanguard Group, Inc.as of 31 Dec 20231.42m2.94%
Citadel Advisors LLCas of 31 Dec 2023724.38k1.50%
Geode Capital Management LLCas of 31 Dec 2023591.15k1.22%
Morgan Stanley & Co. LLCas of 31 Dec 2023453.02k0.94%
SSgA Funds Management, Inc.as of 31 Dec 2023417.25k0.86%
Acuta Capital Partners LLCas of 31 Dec 2023324.60k0.67%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.